Nebivolol Sandoz (Nebivolol)

Nebivolol works by selectively antagonizing β1‑adrenergic receptors, which reduces heart rate and myocardial contractility. At the same time, it stimulates endothelial nitric‑oxide synthase, causing nitric‑oxide release that relaxes blood vessels, leading to lower systemic vascular resistance and improved blood pressure control.

The specific dose of Nebivolol Sandoz is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will provide individualized instructions.

The safety of nebivolol in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebivolol is distinguished by its high β1‑selectivity and additional nitric‑oxide mediated vasodilatory effect, which may result in fewer metabolic side effects and improved endothelial function compared with non‑selective beta blockers. Clinical choice depends on individual patient characteristics and therapeutic goals.

Store Nebivolol Sandoz tablets at below 25 °C in the original container, protecting them from moisture and direct sunlight. Do not expose the product to excessive heat or humidity to maintain its stability and potency.

Nebivolol Sandoz is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, difficulty breathing, or swelling of the face or throat.

Nebivolol Sandoz is contraindicated in patients with severe bradycardia, second‑degree or higher atrioventricular block, cardiogenic shock, or known hypersensitivity to nebivolol or any excipients. Caution is advised in individuals with hepatic impairment, asthma, or chronic obstructive pulmonary disease.